Possible acute rejection associated with the use of the new antihepatitis C virus medications
Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new directacting antiviral agents gave big hopes to both clinicians and patients that they can overcome this...
Main Authors: | Khaled Ar Karkout, Saleema Al Sherif, Qutaiba Hussein, Alia Albawardi, Yousef Boobes |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Avicenna Journal of Medicine |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/AJM.AJM_171_17 |
Similar Items
-
Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes
by: Giovana Rossato, et al.
Published: (2020-01-01) -
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
by: Michael Duerr, et al.
Published: (2019-02-01) -
Recurrent hepatitis C treatment with direct acting antivirals – a real life study at a Brazilian liver transplant center
by: L.P. Zanaga, et al. -
Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
by: Pol S, et al.
Published: (2016-03-01) -
High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017-10-01)